Performance
5 Days
-0.68%
1 Month
3.90%
3 Months
4.06%
6 Months
3.72%
1 Year
17.81%
2 Year
69.99%
Key data
Stock price
$488.29
DAY RANGE
$482.82 - $492.34
52 WEEK RANGE
$377.85 - $519.88
52 WEEK CHANGE
$17.81
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: Reshma Kewalramani
Region: US
Website: vrtx.com
Employees: 4,800
IPO year: 1991
Issue type: Common Stock
Market: XNAS
Industry:
Sector:
Region: US
Website: vrtx.com
Employees: 4,800
IPO year: 1991
Issue type: Common Stock
Market: XNAS
Industry:
Sector:
Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial.
Recent news